Published in J Cell Sci on April 01, 1998
Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol (2010) 3.28
Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med (2007) 1.49
CtBPs promote cell survival through the maintenance of mitotic fidelity. Mol Cell Biol (2009) 1.12
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
The nucleolus directly regulates p53 export and degradation. J Cell Biol (2011) 1.04
53BP1 contributes to a robust genomic stability in human fibroblasts. Aging (Albany NY) (2011) 0.90
Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cells. J Exp Clin Cancer Res (2013) 0.85
Excess F-actin mechanically impedes mitosis leading to cytokinesis failure in X-linked neutropenia by exceeding Aurora B kinase error correction capacity. Blood (2012) 0.81
Role of caspase-3 cleaved IP3 R1 on Ca(2+) homeostasis and developmental competence of mouse oocytes and eggs. J Cell Physiol (2014) 0.79
A variation in the structure of the protein-coding region of the human p53 gene. Gene (1988) 3.03
The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature (1998) 2.86
Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A (1996) 2.66
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A (2008) 1.36
Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene (2011) 1.26
HLA homozygous stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells (2008) 1.22
Chromosome changes caused by alterations of p53 expression. Mutat Res (1996) 1.22
Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. Gene (2005) 1.07
11q deletions in human colorectal carcinomas: cytogenetics and restriction fragment length polymorphism analysis. Genes Chromosomes Cancer (1993) 1.05
Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. Biochemistry (Mosc) (2008) 1.04
Disruption of actin microfilaments by cytochalasin D leads to activation of p53. FEBS Lett (1998) 1.00
P53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints. Oncogene (1999) 0.94
p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system. Cell Biol Int (1999) 0.93
p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene (2001) 0.93
p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett (2008) 0.91
[Retroviral reporter systems for the assessment of activity of stress-induced signal transduction pathways controlled by p53, HIF-1 and HSF-1 transcription factors]. Mol Biol (Mosk) (2005) 0.90
Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett (1988) 0.89
Optimization of a Genome-Wide Disordered Lentivector-Based Short Hairpin RNA Library. Mol Biol (2006) 0.89
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]. Mol Biol (Mosk) (2007) 0.86
Cell-specific effects of RAS oncogene and protein kinase C agonist TPA on P-glycoprotein function. FEBS Lett (1995) 0.86
[Effect of on various cell lines of p53 cDNA, expressed under the control of an exogenous homologous promotor]. Mol Biol (Mosk) (1995) 0.86
Specific karyotypic alterations in colchicine-resistant cells. Cytogenet Cell Genet (1981) 0.86
Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. Gene Ther (2004) 0.86
Karyotype peculiarities of human colorectal adenocarcinomas. Hum Genet (1991) 0.85
[Functional heterogeneity of p53-responsive elements]. Mol Biol (Mosk) (1996) 0.85
[Down-regulation of TRIP6 expression induces actin cytoskeleton rearrangements in human carcinoma cell lines]. Mol Biol (Mosk) (2005) 0.84
[Downregulation of activated leukemic oncogenes AML1-ETO and RUNX1(K83N) expression with RNA-interference]. Mol Biol (Mosk) (2010) 0.83
[Structural organization of the human p53 gene. I. Molecular cloning of the human p53 gene]. Genetika (1987) 0.82
Gene amplification in Djungarian hamster cell lines possessing decreased plasma membrane permeability for colchicine and some other drugs. Chromosoma (1985) 0.82
Transcription of the viral genome in cell lines transformed by simian virus 40. I. Mapping of virus-specific nuclear RNAs. Nucleic Acids Res (1980) 0.81
Cloning and characterization of DNA sequences amplified in multidrug-resistant Djungarian hamster and mouse cells. Somat Cell Mol Genet (1987) 0.81
[Alternative transcripts from POLRMT responsible for synthesis of nuclear RNA polymerase IV]. Mol Biol (Mosk) (2005) 0.81
Comparison of mitostatic effect, cell uptake and tubulin-binding activity on colchicine and colcemid. Biochim Biophys Acta (1981) 0.81
[Isolation of a plasmid clone containing the mRNA sequence for mouse nonviral T-antigen]. Dokl Akad Nauk SSSR (1982) 0.81
Colcemid-induced polyploidy and aneuploidy in normal and tumour cells in vitro. Int J Cancer (1975) 0.80
[Construction of a reporter system for fine quantitative assessment of activity of p53 protein in cultured cells]. Mol Biol (Mosk) (2004) 0.80
Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells. Oncol Res (1997) 0.79
[The protective role of p53 in Ras-induced transformation of REF52 cells]. Mol Biol (Mosk) (2003) 0.79
Regular pattern of karyotypic alterations accompanying gene amplification in Djungarian hamster cells: study of colchicine, adriablastin, and methotrexate resistance. Chromosoma (1985) 0.79
Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts. Oncol Res (1995) 0.79
[Genome-wide lentivector-based pooled shRNA library optimization]. Mol Biol (Mosk) (2006) 0.79
[Apoptin enhances the oncolytic activity of vaccinia virus]. Mol Biol (Mosk) (2014) 0.79
[Oncolytic enteroviruses]. Mol Biol (Mosk) (2012) 0.78
[Oncolytic poxviruses]. Mol Gen Mikrobiol Virusol (2012) 0.78
Constitutive and induced functions of the p53 gene. Biochemistry (Mosc) (2010) 0.78
[Antisense RNA p53 inhibits proliferation of normal and transformed cells]. Mol Biol (Mosk) (1989) 0.78
[Effect of inactivating the p33ING1 tumor suppressor on the function of cell cycle "checkpoints" and genome stability]. Genetika (2000) 0.78
[P66shc action on resistance of colon carcinoma RKO cells to oxidative stress]. Mol Biol (Mosk) (2012) 0.78
The use of syngeneic cells producing human somatotropic hormone (hSTH) for immunization of mice and development of hybridomas. Hybridoma (1990) 0.77
[Two allelic genes of human p53 code for proteins differing with respect to amino acid sequence]. Genetika (1988) 0.77
[Protein complementation as tool for studying protein-protein interactions in living cells]. Mol Biol (Mosk) (2012) 0.77
[The human adenosine deaminase gene contains a p53-responsive element]. Dokl Akad Nauk (1996) 0.77
[Hyperproduction of a specific protein in cells resistant to colchicine and adriablastin]. Biull Eksp Biol Med (1983) 0.77
[Oncotoxic proteins in cancer therapy: mechanisms of action]. Mol Biol (Mosk) (2015) 0.76
[Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives]. Mol Biol (Mosk) (2012) 0.76
[Enhanced control of proliferation in telomerized cells]. Ontogenez (2007) 0.76
[Construction of chimeric tumor suppressor p53 resistant to the dominant-negative interaction with p53 mutants]. Mol Biol (Mosk) (2002) 0.76
[A lentivirus vector based assay system for quantitative detection of intracellular translocations of recombinant proteins]. Mol Biol (Mosk) (2009) 0.76
Decreased sensitivity of multidrug-resistant tumor cells to cisplatin is correlated with sorcin gene co-amplification. Neoplasma (1995) 0.76
[Oncolytic parvoviruses. A new approaches for cancer therapy]. Vestn Ross Akad Med Nauk (2012) 0.76
[Mutation of p53 is necessary for stable transformation of REF52 cells by myc+ras oncogenes]. Mol Biol (Mosk) (2000) 0.76
A chemical method to enrich RNA by molecules having 5'-terminal triphosphate groups. Nucleic Acids Res (1981) 0.75
[Induction of hyperdiploidy and chromosome breaks in LIM1215 cells expressing the exogenous mutant p53]. Genetika (1996) 0.75
[Oncolytic properties of some orthopoxviruses, adenoviruses and parvoviruses in human glioma cells]. Vestn Ross Akad Med Nauk (2013) 0.75
[The use of p53 as a tool for human cancer therapy]. Mol Biol (Mosk) (2008) 0.75
[Regulation of DNA synthesis in the heterokaryons of macrophages and cells immortalized by oncogenes]. Dokl Akad Nauk SSSR (1987) 0.75
Symmetric transcription of simian virus 40 DNA at the early phase of productive infection. Biochem Biophys Res Commun (1979) 0.75
Studies of the UV-sensitivity of virus-specific RNA synthesis in cells infected or transformed by adenovirus 5 and SV 40. Mol Biol Rep (1977) 0.75
[Primary structure of DNA complementary to mRNA of murine oncoprotein p53]. Bioorg Khim (1987) 0.75
[Nuclear viral transcripts in the clone of rat cells transformed by SV40 virus]. Dokl Akad Nauk SSSR (1978) 0.75
[Changes in the gene of the cellular T-antigen (p53) in human tumors]. Dokl Akad Nauk SSSR (1985) 0.75
[Amplification of portions of the genome in mammalian somatic cells resistant to colchicine. VI. Restriction analysis of the amplified DNA sequences]. Genetika (1983) 0.75
[Molecular organization of the complete gene encoding a human cellular tumor antigen (p53)]. Dokl Akad Nauk SSSR (1987) 0.75